ClinicalTrials.gg
CompletedNCT02002832Updated Nov 15, 2019Results posted

A Clinical Trial of Lurasidone in Treatment of Schizophrenia

A Phase 3 interventional study of Lurasidone tablets and Risperidone tablets in Schizophrenia, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Completed at 15 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-15.

Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. (formerly part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
10th of 39
388 · median 149
Started
2013
with 4 others
Phase 3
18 of 39
none open now
Registered
29th of 39
by date
Lead sponsor
5 of 39
Sumitomo Pharma (Suzhou) Co., Ltd.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 10th largest by enrollment, is one of 5 that started in 2013, is one of 18 in phase 3, and was the 29th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
  • Lurasidone
  • LATUDA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written and aged between 18 and 65 years of age.
  • Meets criteria for a primary diagnosis of schizophrenia, had a PANSS total score ≥ 70 and ≤ 120 at Screening and Baseline, and a score ≥ 4 on the CGI-S at Screening and Baseline.
  • Not pregnant, if of agrees to use adequate and reliable for duration of study.
  • Able and agrees to remain off prior antipsychotic medication for the duration of study.
  • Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.

Exclusion criteria

Exclusion Criteria:

  • Considered by the investigator to be at imminent risk of suicide or injury to self, others or property.
  • Any chronic organic disease of the CNS(other than schizophrenia)
  • Subjects are participating or participated in other clinical studies including marketed drugs or medical devices within 30 days before signing the form.
  • or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
388 participants (actual)

Study arms

  • Experimental
    Lurasidone group

    Drug: Lurasidone tablets

  • Active comparator
    Risperidone group

    Drug: Risperidone tablets

Interventions

  • Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)

    Also known as: LATUDA

  • Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores.

    Mean change in Positive and Negative Syndrome Scale total score from baseline to Week 6 at the end of treatment. PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. It have 30 evaluation items, which include 7 positive sub-scale, 7 negative sub-scale and 16 general psychopathology sub-scale on a score of 1 to 7. The total score is the sum of the 30 scale items. The minimum score is 30 and the maximum score is 210. Patient with PANSS total scores\<70 is the normal,but the scores\>120 is more serious.

    Time frame: From baseline to Week 6(day 42).

Secondary outcomes

  1. Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 6.

    The Clinical Global Impression Scale-Improvement (CGI-I) Score is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to baseline state at the beginning of the intervention. Response is rated as one of the following, in which higher scores indicate less improvement or worsening: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, and 7=Very much worse.

    Time frame: From baseline to Week 6(day 42).

07

Results

Posted Apr 1, 2019

Participant flow

Participant flow — Overall Study
MilestoneLurasidone GroupRisperidone Group
Started194194
Completed166168
Not completed2826

Outcome measures

PrimaryMean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores.

Mean change in Positive and Negative Syndrome Scale total score from baseline to Week 6 at the end of treatment. PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. It have 30 evaluation items, which include 7 positive sub-scale, 7 negative sub-scale and 16 general psychopathology sub-scale on a score of 1 to 7. The total score is the sum of the 30 scale items. The minimum score is 30 and the maximum score is 210. Patient with PANSS total scores\<70 is the normal,but the scores\>120 is more serious.

Time frame:
From baseline to Week 6(day 42).
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores.
units on a scaleLurasidone GroupRisperidone Group
Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores.-31.2 (-33.2 to -29.2)-34.9 (-36.8 to -32.9)
Statistical analysis
  • Lurasidone Group vs Risperidone Group · Mixed Models Analysis · Mean difference (final values): 3.7 · 95% CI 1.0 to 6.3
SecondaryMean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 6.

The Clinical Global Impression Scale-Improvement (CGI-I) Score is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to baseline state at the beginning of the intervention. Response is rated as one of the following, in which higher scores indicate less improvement or worsening: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, and 7=Very much worse.

Time frame:
From baseline to Week 6(day 42).
Reported as:
Least squares mean · units on a scale
Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 6.
units on a scaleLurasidone GroupRisperidone Group
Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 6.2.0 (1.9 to 2.1)1.9 (1.8 to 2.0)

Adverse events

Collected over Date of first dose of study medication and up to 7 days after date of last dose of treatment in double-blind phase, an average of 7 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone Group0/194 (0%)1/194 (0.5%)134/194 (69.1%)
Risperidone Group0/191 (0%)0/191 (0%)160/191 (83.8%)
Most frequent serious events
Most frequent serious events
EventLurasidone GroupRisperidone Group
Hand fractureInjury, poisoning and procedural complications1/1940/191
Most frequent other events
Showing 10 of 28
Most frequent other events
EventLurasidone GroupRisperidone Group
Extrapyramidal disorderNervous system disorders33/19473/191
ConsitpationGastrointestinal disorders25/19428/191
NasopharyngitisInfections and infestations19/19428/191
Blood prolactin increasedInvestigations6/19427/191
AkathisiaNervous system disorders14/19426/191
InsomniaPsychiatric disorders19/19419/191
Upper respiratory tract infectionInfections and infestations10/19416/191
AnxietyPsychiatric disorders12/19412/191
Weight increasedInvestigations1/19410/191
DizzinessNervous system disorders5/1948/191

Baseline characteristics

Intent-to-treat population (ITT) : All randomized subjects who received at least one dose of study medication,were included in the Intent-to-treat population.

Age, Categorical
Age, Categorical(Participants)Lurasidone GroupRisperidone GroupTotal
<=18 years000
Between 18 and 65 years194190384
>=65 years000
Age, Continuous
Age, Continuous(years)Lurasidone GroupRisperidone GroupTotal
Mean34.6 ± 11.1234.8 ± 10.7134.7 ± 10.91
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone GroupRisperidone GroupTotal
Female9689185
Male98101199
Region of Enrollment
Region of Enrollment(participants)Lurasidone GroupRisperidone GroupTotal
China194190384
08

Study locations

15 sites
  • Capital Medical University Affiliated Beijing Anding Hospital
    Beijing, Beijing 100088, China
  • Beijing Huilongguan Hospital
    Beijing, Beijing 100096, China
  • Peking University Sixth Hospital
    Beijing, Beijing 100191, China
  • Guangzhou Brain Hospital
    Guangzhou, Guangdong 510370, China
  • HeBei Mental Health Center
    Baoding, Hebei 071000, China
  • Henan Provincial Mental Hospital
    Xinxiang, Henan 453002, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
  • Hunan Province Brain Hospital
    Changsha, Hunan 410007, China
  • Nanjing Brain Hospital
    Nanjing, Jiangsu 210029, China
  • Wuxi Mental Health Center
    Wuxi, Jiangsu 214000, China
  • Shanghai Mental Health Center
    Shanghai, Shanghai 200030, China
  • Xi'an Mental Health Center
    Xi'an, Shanxi 710061, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Anding Hospital
    Tianjin, Tianjin 300222, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Apr 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2019, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2013
First posted
Dec 6, 2013
Start
Dec 2013
Primary completionActual
Apr 2015
CompletionActual
Nov 2015
Results first posted
Apr 1, 2019
Last update
Nov 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02002832
Responsible party
Sponsor
First posted
Dec 6, 2013
Start date
Dec 2013
Primary completion
Apr 2015
Completion
Nov 2015
Results posted
Apr 1, 2019
Last update
Nov 15, 2019

Study contacts

Zhuoji CAI, MD
principal investigator · Capital Medical University Affiliated Beijing Anding Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion